Wednesday, September 23, 2026

The Andersons And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

October 8, 2021

The Andersons  And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

(VIANEWS) - The Andersons (ANDE), Leidos Holdings (LDOS), CONMED Corporation (CNMD) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. The Andersons (ANDE)

19.1% sales growth and 4.37% return on equity

The Andersons, Inc., an agriculture company, operates in trade, ethanol, plant nutrient, and rail sectors in the United States and internationally.

The Andersons's sales growth this year is expected to be 41.2% and 2.3% for next year.

Year-on-year quarterly revenue growth grew by 42.2%, now sitting on 8.99B for the twelve trailing months.

Volume

Today's last reported volume for The Andersons is 60807 which is 57.83% below its average volume of 144206.

The Andersons's sales growth for the next quarter is 19.1%. The company's growth estimates for the current quarter and the next is a negative 28.6% and 16.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.37%.

Volatility

The Andersons's last day, last week, and last month's current volatility was 2.14%, 1.74%, and 1.30%, respectively.

The Andersons's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 4.03% (day), 2.65% (last week), and 2.81% (last month), respectively.

The Andersons's Stock Yearly Top and Bottom Value

The Andersons's stock is valued at $31.43 at 06:22 EST, below its 52-week high of $34.41 and way above its 52-week low of $18.02.

The Andersons's Moving Average

The Andersons's worth is above its 50-day moving average of $30.02 and higher than its 200-day moving average of $29.40.

2. Leidos Holdings (LDOS)

11.7% sales growth and 19.1% return on equity

Leidos Holdings, Inc. provides services and solutions in the defense, intelligence, civil, and health markets in the United States and internationally.

Leidos Holdings's sales growth this year is expected to be 13.9% and 7% for next year.

Year-on-year quarterly revenue growth grew by 18.3%, now sitting on 13.26B for the twelve trailing months.

Volume

Today's last reported volume for Leidos Holdings is 490679 which is 36.02% below its average volume of 767036.

Leidos Holdings's sales growth for the next quarter is 11.7%. The company's growth estimates for the present quarter and the next is 9.5% and 1.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.1%.

Volatility

Leidos Holdings's last day, last week, and last month's current volatility was 1.35%, 1.54%, and 1.46%, respectively.

Leidos Holdings's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.40% (day), 2.33% (last week), and 1.96% (last month), respectively.

Leidos Holdings's Stock Yearly Top and Bottom Value

Leidos Holdings's stock is valued at $97.43 at 06:22 EST, way under its 52-week high of $113.75 and way higher than its 52-week low of $79.15.

Leidos Holdings's Moving Average

Leidos Holdings's value is above its 50-day moving average of $96.38 and under its 200-day moving average of $100.49.

3. CONMED Corporation (CNMD)

11.6% sales growth and 7.63% return on equity

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide.

CONMED Corporation's sales growth this year is expected to be 18.8% and 9.1% for next year.

Year-on-year quarterly revenue growth grew by 61.7%, now sitting on 978.5M for the twelve trailing months.

Volume

Today's last reported volume for CONMED Corporation is 203609 which is 8.59% below its average volume of 222765.

CONMED Corporation's sales growth is a negative 0% for the current quarter and 11.6% for the next. The company's growth estimates for the current quarter and the next is a negative 14.8% and 29.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.63%.

Volatility

CONMED Corporation's last day, last week, and last month's current volatility was 2.87%, 1.48%, and 1.38%, respectively.

CONMED Corporation's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 4.16% (day), 3.33% (last week), and 2.81% (last month), respectively.

CONMED Corporation's Stock Yearly Top and Bottom Value

CONMED Corporation's stock is valued at $129.86 at 06:22 EST, way under its 52-week high of $146.95 and way higher than its 52-week low of $76.43.

CONMED Corporation's Moving Average

CONMED Corporation's value is above its 50-day moving average of $129.38 and below its 200-day moving average of $133.35.

4. Discovery Inc (DISCA)

10.1% sales growth and 9.5% return on equity

Discovery, Inc. operates as a media company in the United States and internationally.

Discovery Inc's sales growth this year is expected to be 14% and 4.4% for next year.

Year-on-year quarterly revenue growth grew by 4.1%, now sitting on 10.78B for the twelve trailing months.

Volume

Today's last reported volume for Discovery Inc is 6703320 which is 21.27% above its average volume of 5527220.

Discovery Inc's sales growth for the next quarter is 10.1%. The company's growth estimates for the present quarter and the next is a negative 51.9% and 14.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.5%.

Volatility

Discovery Inc's last day, last week, and last month's current volatility was 1.42%, 3.68%, and 1.91%, respectively.

Discovery Inc's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.68% (day), 2.58% (last week), and 2.79% (last month), respectively.

Discovery Inc's Stock Yearly Top and Bottom Value

Discovery Inc's stock is valued at $26.46 at 06:22 EST, way below its 52-week high of $78.14 and way higher than its 52-week low of $19.07.

Discovery Inc's Moving Average

Discovery Inc's worth is below its 50-day moving average of $26.97 and way under its 200-day moving average of $32.54.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,304 source documents archived
Query this data → isubstrate.com